A Boston-based biotechnology company has dosed the first patient in a Phase 1 clinical trial of a drug designed to reverse age-related vision loss by resetting the epigenetic code of damaged cells. The therapy, called ER-100, is the first cellular rejuvenation treatment using epigenetic reprogramming to reach human trials.
Life Biosciences announced the milestone Monday. The trial is evaluating ER-100 in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), two leading causes of irreversible blindness in older adults for which no disease-modifying treatments currently exist.
“ER-100 is the first ever cellular rejuvenation therapy using epigenetic reprogramming to receive FDA clearance to enter human clinical trials,” the company said in a statement.
How it works
ER-100 is built on Life Biosciences’ Partial Epigenetic Reprogramming platform, which uses controlled delivery of three transcription factors known as OSK: OCT4, SOX2, and KLF4. These are three of the four Yamanaka factors, the Nobel Prize-winning discovery that showed adult cells can be reprogrammed to an embryonic-like state.
Life Bio’s approach is more limited: instead of fully reprogramming cells, which carries cancer risks, the therapy partially resets the epigenome, the system of biochemical markers that regulates which genes are active without altering the underlying DNA sequence. As cells age, their epigenetic patterns degrade, leading to diminished function. The company’s hypothesis is that restoring those patterns to a younger state can rejuvenate damaged tissue.
“This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, PhD, co-founder of Life Biosciences and professor of genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”
The therapy is delivered by intravitreal injection directly into the eye. Preclinical studies in animal models demonstrated “controlled OSK expression, restoration of methylation patterns, and improved visual function,” according to the company.
The medical need
Optic neuropathies destroy retinal ganglion cells, the neurons that connect the eye to the brain. Because these cells cannot regenerate, damage results in permanent vision impairment. Open-angle glaucoma, a chronic neurodegenerative disease and a leading cause of blindness, affects millions worldwide. While often associated with elevated intraocular pressure, retinal damage frequently continues despite treatment, and some patients develop glaucoma even with normal pressure.
NAION, often called a “stroke of the eye,” is the most common acute optic neuropathy in adults over 50, causing sudden, painless vision loss due to insufficient blood flow. There are currently no approved treatments.
“Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells,” the company noted. “As a consequence, the disease often leads to irreversible vision loss despite treatment.”
What happens next
The Phase 1 trial (NCT07290244 on clinicaltrials.gov) is focused on safety and tolerability, with additional endpoints assessing visual function. The FDA cleared Life Bio’s Investigational New Drug application in January 2026, with Nature Biotechnology publishing coverage of the milestone in February.
The company is already looking beyond ophthalmology. “Beyond ER-100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform.”
Sinclair’s involvement gives the project significant scientific credibility. His lab at Harvard has been a central driver of epigenetic aging research, and his public advocacy for reprogramming as a therapeutic strategy has made him one of the most recognized figures in longevity science. But translating lab findings into approved drugs has historically been the hardest part of the aging biology field. ER-100’s first patient dose marks the beginning of that translation, not the end. The trial will need to demonstrate not just safety but meaningful visual improvement, and even then, the path from Phase 1 to FDA approval typically takes years.
The therapy represents a genuine first: the first time a drug designed to reverse aging at the epigenetic level has been tested in a human being. Whatever the trial’s outcome, that is a milestone worth marking.
—
Sources: Life Biosciences (January 28, 2026); BioSpace (June 9, 2026); Wired (June 9, 2026); Nature Biotechnology (February 17, 2026)